{"filing":{"accession_number":"0001654954-26-008318","cik":"0001131399","ticker":"GLAXF","company_name":"GSK plc","form":"6-K","filing_date":"2026-09-14","report_date":"2026-09-14","primary_document":"a5235u.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1131399/000165495426008318/a5235u.htm"},"events":[{"id":33101,"run_id":30425,"accession_number":"0001654954-26-008318","anchor_item_number":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.25,"summary":"This is a clinical trial results announcement for Jideytro (zidesamtinib) in ROS1-positive NSCLC, presented at the 2026 World Conference on Lung Cancer. The disclosure reports positive Phase I/II ARROS-1 trial data (94% ORR, 90% PFS at 12 months) and states that results \"will support a planned supplemental New Drug Application to the US FDA this year to expand the indication for Jideytro to include first-line treatment.\" However, this is not a financial earnings release disclosing quarterly or annual results; it is a clinical/operational milestone announcement regarding a drug development program. The event is material to investors as it affects the commercial prospects of a key product, but the classification as \"earnings_release\" is a poor fit—this is more accurately an operational or regulatory milestone that does not match any single taxonomy category precisely.","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-09-14","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":36448,"accession_number":"0001654954-26-008318","item_number":null,"item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.25,"reasoning":"This is a clinical trial results announcement for Jideytro (zidesamtinib) in ROS1-positive NSCLC, presented at the 2026 World Conference on Lung Cancer. The disclosure reports positive Phase I/II ARROS-1 trial data (94% ORR, 90% PFS at 12 months) and states that results \"will support a planned supplemental New Drug Application to the US FDA this year to expand the indication for Jideytro to include first-line treatment.\" However, this is not a financial earnings release disclosing quarterly or annual results; it is a clinical/operational milestone announcement regarding a drug development program. The event is material to investors as it affects the commercial prospects of a key product, but the classification as \"earnings_release\" is a poor fit—this is more accurately an operational or regulatory milestone that does not match any single taxonomy category precisely.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-14T11:04:49.218342+00:00","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-09-14"}]}